Abstract
Ustekinumab is a monoclonal antibody administered as a weight-based intravenous (IV) induction, followed by 90 mg subcutaneous injections every 8 weeks for the treatment of Crohn's disease. We report 6 patients who were administered IV ustekinumab every 12 weeks for maintenance therapy due to financial constraints in place of the standard dosing regimen. All patients tolerated IV ustekinumab, and no adverse events occurred to this point. Two patients achieved clinical and endoscopic remission, and 4 patients achieved clinical remission and are awaiting future endoscopic assessment.